- Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials - Patients will have no out-of-pocket costs for the medication INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S.
- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes -
‒ Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease ‒ These Phase 2 data reinforce the continued evaluation of mirikizumab in the ongoing, pivotal VIVID Phase 3
- Largest Real-World Study of Patient-Reported Outcomes in People with Migraine Shows the Use of Novel CGRP Monoclonal Antibody Class May Improve Migraine INDIANAPOLIS , Oct. 9, 2020 /PRNewswire/ -- Nearly 80% of people taking calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) for
Further results from NIAID-sponsored ACTT-2 Trial Presented Today INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical
- Lilly submitted request for emergency use authorization (EUA) for monotherapy to U.S. Food and Drug Administration (FDA) - New data show combination therapy met primary and secondary endpoints, reducing viral load, symptoms and hospitalizations; EUA request to follow - Plan to initiate a
Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each INDIANAPOLIS and SAN DIEGO , Oct. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DexCom, Inc.
Patients on REYVOW had 3.8-7.2 Times Greater Odds of Achieving Pain Freedom at 2 Hours Versus Placebo in At Least 2 out of 3 Attacks, Resulting in Significant Therapeutic Gains of 10-20% INDIANAPOLIS , Oct. 6, 2020 /PRNewswire/ -- Adults who took REYVOW ® (lasmiditan) C-V for their migraine attacks
Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer The Phase 3 monarchE trial evaluating the effects of two years of Verzenio treatment added to
Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for